Clinicians in the real world are going to have patients who are clearly unresectable/have metastases, and then the rest for whom either surgery is an option or there's advanced local disease but it looks unresectable for technical reasons expertly outlined by you..
I suspect that, again in the real world, anything that makes the surgeons deal with a smaller tumour (even if it was clearly resectable) is going to be used.
BR might have definitions for the purposes of research, but the definitions for standard pre-op use of chemo and RT/oncosil will be more flexible.
And as far as research goes, the comparators need to be clear. You're comparing (pre-surgery) C+RT (either oncosil or other) against chemo alone. Then maybe oncosil vs other forms of RT.
But there are ethical issues in witholding treatment options in a disease with so few options as pancreatic cancer.
I personally think the acceptable RCTs will be smaller than people imagine.
OSL Price at posting:
12.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)